Login
Cart
Support
Search
Search
Search
DDW 2024 On Demand
John Martinez
Appearances
View Grid
PATIENTS WITH MAFLD TAKING GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT HAVE HIGHER INCIDENCE FOR HEPATOBILIARY CANCER BUT HAVE LOWER OVERALL MORTALITY: A MULTI-CENTER ANALYSIS.
Date
May 20, 2024
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects one in four people globally and is the primary cause of chronic liver disease. MAFLD is associated with a nearly 1.5-fold to 2-fold increased risk of developing GI cancers…
Presenter
Luis Nieto
Speakers
Pedro Palacios Argueta
Sharon Narvaez
John Martinez
Laura Davisson
Kenneth Vega